Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Sign up Log in

MEMPHASYS LIMITED. AGM Information 2011

Nov 28, 2011

65314_rns_2011-11-28_8ab850a1-b9a7-44c1-add4-e2d9fbf3ed9f.pdf

AGM Information

Open in viewer

Opens in your device viewer

NuSep AGM 29 November 2011

Agenda

• R
i
i
&
W
l
t
t
e
g
s
r
a
o
n
e
c
o
m
e		 1
0.
1
5
a
m
• F
i
i
l
R
t
n
a
n
c
a
e
p
o
r
s		 1
0.
3
0
a
m
• R
l
i
1
R
i
R
t
t
t
e
s
o
u
o
n
e
m
u
n
e
r
a
o
n
e
p
o
r
–		 1
0.
4
0
a
m
• i
i
f
i
i
f
i
f
R
l
2
R
M
J
h
t
t
t
t
t
e
s
o
u
o
n
a
c
a
o
n
o
a
p
p
o
n
m
e
n
o
r
o
–		 'C
O
n
o
n
n
o
r		 1
0.
5
0
a
m
• R
l
i
R
i
f
i
i
f
i
f
M
D
i
3
t
t
t
t
t
e
s
o
u
o
n
a
c
a
o
n
o
a
p
p
o
n
m
e
n
o
r
a
v
–		 d
R
f
f
o
e		 1
1.
0
0
a
m
• R
l
i
R
i
f
i
i
f
i
f
M
W
4
t
t
t
t
t
e
s
o
o
n
a
c
a
o
n
o
a
p
p
o
n
m
e
n
o
r
a
r
u
–		 d
W
t
t
e
s
c
o		 1
1.
1
0
a
m
• R
l
i
5
R
i
i
i
R
l
i
i
t
t
t
t
t
e
s
o
o
n
e
q
s
o
n
e
s
o
o
n
a
p
p
o
n
m
e
n
o
u
u
u
–		 f
D
N
i
b
t
r
s
e		 1
1.
2
0
a
m
• R
l
i
6
R
i
i
i
R
l
i
i
t
t
t
t
t
e
s
o
u
o
n
e
q
u
s
o
n
e
s
o
u
o
n
a
p
p
o
n
m
e
n
o
–		 f
M
O
'D
r
w
y
e
r		 1
1.
3
0
a
m
• R
l
i
P
l
l
t
e
s
o
u
o
n
o		 1
1.
4
0
a
m
• i
i
E
P
t
t
t
x
e
c
u
v
e
r
e
s
e
n
a
o
n		 1
1.
5
0
a
m
• M
i
l
t
e
e
n
g
c
o
s
e		 1
2
n
o
o
n

Financial Reports

  • •10.15am to 10.30am
  • • To receive and consider the consolidated financial report of the Company and the reports of the directors and the auditors for the financial year ending 30 June 2011.

Resolution 1 – Remuneration Report

•10.30am to 10.40am

  • • To consider and, if thought fit, to pass the following resolution as an ordinary resolution:
  • • "In accordance with section 250R(2) of the Corporations Act 2001 (Cth), that the remuneration report of the Company for the financial year ending 30 June 2011 be adopted."
  • • The vote on this resolution is advisory only and does not bind the directors of the Company.
  • •

For 47,015,096 Against 16,317,340

Resolution 2 – Ratification of appointment of Mr John O'Connor

  • •10.50am to 11.00am
  • • To consider and, if thought fit, to pass the following resolution, in accordance with Section 201H(3) of the Corporations Act, as an ordinary resolutions:
  • • That the appointment by the Board of Mr John O'Connor as a director of the Company on Monday 10 October 2011 be ratified.

•

Resolution 3 – Ratification of appointment of Mr David Roffe

  • •11.00am to 11.10am
  • • To consider and, if thought fit, to pass the following resolution, in accordance with Section 201H(3) of the Corporations Act, as an ordinary resolution:
  • • That the appointment by the Board of Mr David Roffe as a director of the Company on Monday 10 October 2011 be ratified.

•

Resolution 4 - Ratification of appointment of Mr Ward Wescott

  • •11.10am to 11.20am
  • • To consider and, if thought fit, to pass the following resolution, in accordance with Section 201H(3) of the Corporations Act, as an ordinary resolution:
  • • That the appointment by the Board of Mr Ward Wescott as a director of the Company on Monday 10 October 2011 be ratified.
  • For 57,296,207 Against 2,823,211

•

Resolution 5 – Requisition Resolution appointment of Dr Nisbet

  • •11.20am to 11.30am
  • • To consider and, if thought fit, to pass the following resolution requisitioned by the shareholders in accordance with section 249N of the Corporations Act as an ordinary resolution:
  • • That Mr Ian Nisbet be appointed as a director of the Company with effect from the conclusion of the AGM.
  • •

Resolution 6 – Requisition Resolution appointment of Mr O'Dwyer

  • •11.30am to 11.40am
  • • To consider and, if thought fit, to pass the following resolution requisitioned by the shareholders in accordance with section 249N of the Corporations Act as an ordinary resolutions:
  • • That Mr Terry O'Dwyer be appointed as a director for the Company with effect from the conclusion of the AGM.
  • •

Resolution Poll

•11.40am to 11.50am

Executive Presentation

AGM November 2011

DISCLAIMER

  • This presentation is not and does not form part of any offer, invitation or recommendation in respect of securities. Any decision to buy or sell NuSep securities or other products should be made only after seeking appropriate financial advice. Reliance should not be placed on information or opinions contained in this presentation and subject only to any legal obligation to do so, the Company does not accept any obligation to correct or update them. This presentation does not take into consideration the investment objectives, financial situation or particular needs of any particular investor.
  • To the fullest extent permitted by law, NuSep and its affiliates and their respective officers, directors, employees and agents, accept no responsibility for any information provided in this presentation, including any forward looking information, and disclaim and liability whatsoever (including for negligence) for any loss howsoever arising from any use of this presentation or reliance on anything contained in or omitted from it or otherwise arising in connection with this.

Corporate Divisions

NuSep's Technology Roadmap

Gels Division

  • •Settled legal cases with Thermo and Expedeon
  • •New line of NuBlu Instant Stain
  • •Increased Orders from Thermo
  • •Appointment of InVitro as Australian Distributors
  • • Strong orders from overseas distributors including Generon in the UK
  • •Pass rates of 90%
  • •Higher production levels

Diagnostics Division

  • •Australian Sales growing
  • •TGA audit of Diagnostic Division in progress
  • •If successful ability to launch unique CBA kit
  • • TGA will also open international markets especially Europe

ProteoIQ

  • • Appointment of Attilio Baldassi as President Americas.
  • • Agreement with major Biotech for consultancy on ProteoIQ. Similar agreements being negotiated with other companies including OEM with major Mass Spec manufacturer.
  • •Significantly increased sales noted since July 2011.

SpermSep

  • • Conversion of 15 cent options allow us to Start clinical trials of SpermSep
  • •Final design phase of Clinical Equipment
  • •Planning completed for sites for Clinical trial
  • • CROs interviewed with a view of appointment for Clinical trial

PrIME Singapore Developments

  • • Employed Director GMP Operations, Director Regulatory Affairs and Director Finance and Administration
  • •Receive Singapore Government Funding & Support
  • •DCS Healthcare Pte Ltd to be cornerstone financier
  • • Completion of Financing agreement due in December 2011
  • • Toll Manufacturing Agreement being finalised with Indian Company

More from MEMPHASYS LIMITED.

Regulatory Filings 2026
Jun 1
Regulatory Filings 2026
May 26
Director's Dealing 2026
May 24
Director's Dealing 2026
May 24
Board/Management Information 2026
May 18
Governance Information 2026
May 3
Interim / Quarterly Report 2026
Apr 16
Investor Presentation 2026
Apr 6
Investor Presentation 2026
Apr 1
Capital/Financing Update 2026
Mar 19
View all filings →